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Background: Elastin gene mutations have been associated with a variety of phenotypes. Autosomal dominant cutis
laxa (ADCL) is a rare disorder that presents with lax skin, typical facial characteristics, inguinal hernias, aortic root
dilatation and pulmonary emphysema. In most patients, frameshift mutations are found in the 3’ region of the
elastin gene (exons 30-34) which result in a C-terminally extended protein, though exceptions have been reported.
Methods: We clinically and molecularly characterized the thus far largest cohort of ADCL patients, consisting of 19
patients from six families and one sporadic patient.
Results: Molecular analysis showed C-terminal frameshift mutations in exon 30, 32, and 34 of the elastin gene and
identified a mutational hotspot in exon 32 (c.2262delA). This cohort confirms the previously reported clinical
constellation of skin laxity (100%), inguinal hernias (51%), aortic root dilatation (55%) and emphysema (37%).
Conclusion: ADCL is a clinically and molecularly homogeneous disorder, but intra- and interfamilial variability in the
severity of organ involvement needs to be taken into account. Regular cardiovascular and pulmonary evaluations
are imperative in the clinical follow-up of these patients.
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Elastin gene (ELN) mutations have been associated with
various skin, cardiovascular and pulmonary phenotypes.
Microdeletions of the region on 7q11, encompassing the
ELN gene, result in Williams-Beuren syndrome (WBS,
OMIM #194050) [1]. This recognizable entity combines
mental retardation with a happy demeanor, typical facial
gestalt, a soft, slightly elastic and doughy skin, hyper-
calcaemia, and arterial stenoses, mainly of the supra-
valvular aorta. A related disorder is the supravalvular
aortic stenosis (SVAS, OMIM #185500) phenotype.
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distribution, and reproduction in any mediumfeatures encountered in the WBS, but do show arterial
stenoses. SVAS is caused by missense and premature trun-
cation mutations that are dispersed throughout the ELN
gene [2].
In contrast, frameshift mutations at the 3’ terminus
that result in a C-terminally elongated and secreted elas-
tin protein [3-8] have been identified in autosomal dom-
inant cutis laxa (ADCL, OMIM #123700). This disorder
comprises generalized skin redundancy, pulmonary em-
physema and aortic root dilatation (ARD).
Different mechanisms underlying the perturbations sub-
sequent to elastin mutations have been identified. In gen-
eral, reduced elastin secretion and deposition, resulting in
increased vascular smooth muscle cell proliferation and a
higher number of smaller elastic lamellae, induces a
phenotype dominated by arterial stenoses [9], while aber-
rant elastin protein production infers to elastic fibertral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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and/or emphysema [3].
To date, frameshift mutations in the 3’UTR of the
elastin gene have been identified in 11 probands with
ADCL, but it remains a matter of debate whether other
molecular mechanisms could be involved. Indeed, two
reports indicated a different molecular basis including a
heterozygous mutation in exon 25 of the elastin gene
[10], and a tandem duplication in the fibulin-5 gene [11],
respectively. Moreover, in the absence of large patient
cohorts, the ADCL phenotype is still insufficiently
characterized and not always easy to discern from
related forms of cutis laxa. Furthermore, the identifica-
tion of an ELN variant in exon 34 (c.2318G>A; p.
(G773D)) complicated genotype-phenotype correlations
in the ELN gene. This variant was associated with pul-
monary emphysema [12] and, in conjunction with a p.
G202R alteration in the fibulin-5 protein, with acquired
cutis laxa following a parasitic infection [13]. Finally, a
case report mentions causal involvement of the ELN
gene in a recessive form of cutis laxa due to a p.(P211S)
alteration [14].
We report on six novel ADCL families, comprising 19
patients, and one sporadic patient, with a review of the
literature. Our data favor homogeneity both at the clin-
ical and molecular level.Methods
Clinical data
Patients were evaluated by an experienced clinical gen-
eticist or dermatologist. Written informed consent was
obtained from each patient and family member before
sample collection. Specific consents were obtained for
publication of the clinical pictures. This study was
approved by the medical ethical committee of Inserm
(France) and of the Ghent University Hospital and the
Declaration of Helsinki Principles were respected.Mutation screening
Genomic DNA was extracted from peripheral blood
leukocytes at Genethon’s DNA Bank using standard
procedures, followed by touchdown PCR amplification
and sequencing of exons 28 through 34 of the ELN gene
as previously described [3]. Sequences were compared to
the wild-type sequence as submitted to Ensembl Accession
number ENST00000358929. Nucleotides were numbered
starting from the first base of the initiation codon
(ATG) of the cDNA reference sequence. Amino acid
residues are numbered from the first methionine resi-
due of the reference sequence. Segregation was verified
in all families and mutations were absent in a panel of
100 Caucasian controls.Results
Clinical data
We present six families and one sporadic patient (S1:II-
2) with ADCL. Pedigrees of the families are presented in
Figure 1. Family 1 originates from the Netherlands, Fam-
ily F2 from Switzerland, and all others from France.
Twenty of the 27 patients were available for clinical
evaluation (Table 1). Male to female ratio was 15/12.
Curiously, in 20 out of 22 meioses the phenotype was
inherited (Χ2=8.84; p-value=0.003). Ages at last clinical
evaluation ranged from 1 to 84 years, with 11 patients
being over 21 years old.
All patients had areas of cutis laxa. A minority of
patients (25%) showed skin redundancy only in the fa-
cial, neck, inguinal and/or axillary regions, while 75% of
patients had extensive to generalized cutis laxa. The fa-
cial skin showed a spectrum ranging from a coarse face
over an aged appearance to overt cutis laxa. Especially
the lower half of the face and neck region were involved
with sagging cheeks, a flabby skin around the chin and
skin redundancy in the neck region. Blepharochalasis
and ptosis of the upper eyelid were often present
(Figure 2J). The skin of the limbs was relatively spared.
Overall, the skin had a soft feeling to the touch with
variable hyperextensibility (Figure 2L). Skin abnormal-
ities tended to improve with age but were highly variable
between and within families. Surgery both for aesthetic
reasons [sagging breasts (F1:II-2, F1:III-1) or lax abdom-
inal skin (F2:I-1 and F2:II-1)] and for functional reasons
[ptosis (F1:II-2)] was disappointing with frequent re-
lapse. Wound healing was reported normal, although F1:
III-1 mentioned recurrent superficial erosions, wound
infections and nail fragility.
Craniofacial dysmorphism was mild but recognizable
and showed a long face, large pliant ears, and a long
philtrum (Figure 2). A beaked nose was present in most
patients (70%).
Inguinal hernias were frequent, appearing congenitally
(F1:II-2, F1:II-3, F1:III-1, F2:II-1) or throughout life (F1:
I-2 at age 80 and F1:III-4 at 18 years old) and often re-
occurred after surgery (patient F1:II-2, F1:II-3, F1:II-3,
F1:III-1). Patient F1:II-4 also had an umbilical hernia.
Systemic involvement was noted in 15 out of 20 patients
(75%). Chronic obstructive pulmonary disease was diag-
nosed in eight patients, seven of whom had emphysema
and one had asthma. F1:II-2 and F1:II-1 were significant
smokers and the latter died at age 55 due to end-stage
respiratory failure with emphysematous lung changes.
Vascular involvement included ARD in eight patients,
and a dilatation of the aortic arch in one (patient
F4:II-2). In addition, patient F3:II-2 had pulmonary ar-
tery dilatation and patient F6:II-1 had a global but stable
increase of the diameters of the arteries, especially of
the carotid arteries (diameter increase of 30%). Four
Figure 1 Pedigrees of the families described in this study. Round symbol, female; square, male; filled symbol, affected; open symbol, normal;
slash line, deceased.
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F5:II-3, F6:II-1), patient F1:II-3 had tricuspid valve
stenosis, and patients F1:II-4 and F6-20 had mitral valve
regurgitation. Other manifestations included gastro-
oesophageal reflux (F1:II-7 and F1:III-4), urogenital
prolapse (F1:II-2), and a hoarse voice (F2:I-1, F2:II-1, F3:
II-1, and F3:II-2).
Hypomobility of spermatozoids required in vitro ferti-
lization for one patient (F1:II-3). None of the patients
reported ocular problems. Growth and psychomotor
development were appropriate in all patients.
Genetic analysis
The ELN mutations identified in these families are
reported in Table 2 and Figure 1. We found three novel
mutations: p.2189delG; p.(Gly730Alafs*25) and c.2142delG;
p.(Leu715Serfs*40) in exon 30; and c.2365delC; p.(Arg789
Glyfs*30) in exon 34. One previously reported mutation
(c.2262delA (p.Gly156Valfs*63)) in exon 32 was found in
four families and may represent a mutational hotspot. All
mutations are predicted to result in a C-terminal missense
sequence with a read-through in the 3’ UTR. Although
exon 30 mutations induce a premature truncation in exon
32, (partial) splicing of this exon will result in a C-
terminally elongated missense protein as previously
reported for similar mutations [3,5].
Genotype-phenotype correlation
There are no obvious genotype-phenotype correlations
when comparing patients with mutations in differentexons (Table 3). The recurrent c.2262delA mutation
shows large interfamilial variability. Moreover, family 1,
3 and 5 also document high intrafamilial variability, both
in skin features and internal organ involvement.
Although the risk for ARD was suggested to be smaller
in patients with exon 32 mutations [3], we did identify
vascular involvement in this patient subgroup. However,
ARD seems more prominent in association with exon 30
mutations (Table 3), but further confirmation is needed.
Discussion
We present the largest patient cohort with ADCL thus
far. The phenotype is homogeneous and comprises
generalized skin involvement, inguinal and umbilical
hernias, ARD and emphysema. The disorder shows full
penetrance, but with variable expression. The aspect and
topography of the skin lesions is highly variable but the
skin changes are most pronounced on the axillar, in-
guinal, neck and lower facial regions. In congruence with
earlier reports [5,8], skin manifestations improve with
aging and the phenotype may be unrecognized in older
patients. Although ADCL is often considered ‘benign’,
systemic involvement, although variable, is frequently
present. Both lung (present in 35% of patients) and aor-
tic involvement (present in 57% of patients) have led to
premature death [5,7]. Patient management therefore
warrants close monitoring of pulmonary function and
aortic root diameters. No current treatment guidelines
are available for ADCL patients. Because earlier reports
Table 1 Clinical details of the patients available for clinical evaluation
Patient Sex,
Age (y)
Skin Inguinal
hernia
Cardiovascular Pulmonary
emphysema
Other
Aspect Topography Left (L)/Right
(R)/Bilateral
(B) (times
surgery)
Trunk Axillar
region
Inguina
region
Limbs Neck Face
F1:I-1 F, 84 Redundant + + + L (1) - + Bilateral ptosis, sagging breasts,
pelvic prolapse
F1:II-2 M, 59 Smooth, sagging, loose + + + + B (10). - + Pliant ears
F1:II-3 M, 57 Smooth, redundant
sagging
+ + + B (12) TVS ARD + Nycturia, decreased fertility
F1:II-4 M, 53 Sagging loose, sagging,
redundant
+ + + + + B (15) ARD (85mm – surgery),
AR, MR
+ Umbilical hernia
Inguinal hernia surgery (13
times)
F1:II-5 F, 51 Sagging loose, sagging,
redundant
+ + + + + - - -
F1:II-7 M, 46 Loose, sagging + + + - - - Gastroesophageal reflux disease,
strabismus
F1:III-1 F, 23 Sagging, loose,
redundant
+ + + + B (2) - - Sagging breasts
F1:III-4 M, 22 Sagging + + R (2) ARD - Gastroesophageal reflux disease,
coarse face
F2:I-1 M, 48 Redundant + + - - + Hoarse voice, corrective skin
surgery
F2:II-1 F, 21 Redundant + + B (0) MVP + Hoarse voice, corrective skin
surgery (3 times)
F3:I-2 F, 31 Excessive, sagging + + + + + + - ARD -
F3:II-1 M, 7 Excessive, sagging + + - ARD - Hoarse voice
F3:II-2 M, 4 Excessive, sagging + + + + + + - Pulmonary artery dilatation Asthma Atopic dermatitis, hoarse voice
F4:II-1 M, 16 Redundant + + + + - ARD Coarse face
F4:II-2 M, 14 - + - Dilated aortic arch (27mm) Coarse face
F5:II-1 F, 14 Excessive, sagging + + + + + + - - - Labiae major coalescence
F5:II-2 M, 10 Excessive, sagging + + + + + + - AR - Testis ectopia
F5:II-3 F,7 Excessive, sagging + + + + + + - AR, Borderline ARD
(23mm)
-
S1:II-2 M, 1 Excessive, sagging, + + + + - ARD
F6:II-1 M, 39 Redundant + + + - AR, global increase of
arterial diameter
-
M, male; F, female; y, years; L, left; R, right; B, bilateral; AR, aortic valve regurgitation; ARD, aortic root dilatation; MVP, mitral valve prolapse; MR, mitral valve regurgitation; TVS, tricuspid valve stenosis. F1 to F6: familial
cases, S1: sporadic case.
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Figure 2 Clinical aspects of affected patients. Facial characteristics include large ears, a long, coarse face, blepharochalasis, ptosis, a beaked
nose and a large philtrum. Note the variability of skin phenotype at different ages. (A-C) Typical facial characteristics, slightly hyperextensible skin,
mild rimpling and sagging of the abdominal skin in patient F3:I-2. (D-F) Typical facial characteristics, slightly hyperextensible skin, and small
redundant skin folds of the axillar folds in patient F3:II-1. (G-I) Typical facial characteristics, manifest loose, redundant and sagging skin folds of the
abdominal skin and slightly hyperextensible skin of the limbs in patient F3:II-2. (J) Patient S1:II-2 at the age of 1 year presenting with typical facial
characteristics and generalized, loose, redundant skin folds. (K-L) Facial characteristics and skin hyperextensibility in patient F6:II-1.
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[3], thresholds for aortic surgery could be based on simi-
lar parameters as in elastinopathies/TGFβ signalopathies
associated with ARD (actual aortic diameter, rate of aor-
tic growth, family history, the patient’s estimation of the
risk, and pregnancy wish) [15]. Moreover, this mechan-
ism might reveal a role for treatment with losartan, anTable 2 ELN mutations identified in this cohort
Patients Origin cDNA level Protein level
Family 1 Netherlands c.2365delC (exon 34) p.(Arg789GlyfsX30)
Family 2 Switzerland c.2189delG (exon 30) p.(Gly730AlafsX25)
Family 3 France c.2262delA (exon32) p.(Gly156ValfsX63)
Family 4 France c.2262delA (exon32) p.(Gly156ValfsX63)
Family 5 France c.2262delA (exon32) p.(Gly156ValfsX63)
Sporadic case France c.2142delG (exon 30) p.(Leu715Serfsx40)
Family 6 France c.2262delA (exon32) p.(Gly156ValfsX63)angiotensin II type 1 receptor blocker with TGFβ antag-
onistic effect. Surgery for skin manifestations and her-
nias is disappointing and should be discouraged if done
purely for aesthetic reasons.
The phenotype can be distinguished from autosomal
recessive types of cutis laxa (ARCL) based on facial ge-
stalt, the absence of skeletal, ocular, and central nervous
involvement (type 2 and 3 ARCL) [16,17], and the ab-
sence of severe early onset emphysema and gastrointes-
tinal and genitourinary diverticula (type 1a/c ARCL [18])
or arterial involvement (type 1b related cutis laxa) [19]
(Table 4). The small number of patients described to
date does not allow drawing straight-forward genotype-
phenotype correlations, although a tendency for a milder
vascular phenotype exists in exon 32 mutations. Mutations
in this exon might be partially rescued by enhanced splicing
of this exon [3].
The clinical homogeneity of the phenotype corresponds
to a striking molecular homogeneity with mutations found
Table 3 Genotype – phenotype correlations in ADCL
Missense F/M individuals Mean age FH IH FG ARD BAV VA Emphys transmission
Exon 30 5/7 21.9 50 64 100 82 10 70 40 100
Exon 32 6/6 17.1 90 17 100 50 0 25 0 95
Exon 33 2/2 21 33 50 100 50 25 50 100 100
Exon 34 3/5 49.5 100 75 100 38 0 25 50 91
Chr rearr 3/0 42 100 67 100 ? 0 0 100 56
Total 19/20 27.3 63 50 100 57 5 38 35 83
Frequencies (%) of the clinical characteristics are given for mutations in the different exons. Chr rear, Chromosomal rearrangement as described by [7]. Mean age
in years. F, female; M, male; FH, family history; IH, Inguinal hernia; FG, Facial gestalt; ARD, aortic root dilatation; BAV, bicuspid aortic valve; VA, other valve
anomalies; Emphys, emphysema. References: [3-8].
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exons 30, 32, 33, and 34 and result in a missense and
elongated sequence at the C-terminus of the elastin pro-
tein [3-8]. Mutation analysis should focus firstly on these
exons, although splice site mutations elsewhere in the
ELN gene could also result in a C-terminal extension
of the protein. Frameshift mutations resulting in C-
terminal protein extensions have been identified in a
variety of other diseases resulting in mislocalization,
altered secretion, increased or decreased stability, resist-
ance to proteases, loss-of-function, gain-of-function,
and novel functions of the affected protein [23-28].
Extended proteins may also result from impaired
processing of propeptides. A well-known example with-
in the field of connective tissue disorders is the Ehlers-
Danlos syndrome type VII that results from mutations
in the substrate collagen type 1 or in its type 1
procollagen N-proteinase (type VIIC). In both cases the
N-terminus of the procollagen type 1 is not removed
and the mutant collagen is deposited into the extracellu-
lar matrix with severe dermal and internal organ
consequences [29,30]. In ADCL it was shown that the
altered and extended C-terminus resulted in increasedTable 4 Clinical characteristics of ADCL and type 1 recessive c
ADCL ARCL type Ia
(ELN) (FBLN5)
Dysmorphism Long philtrum,
beaked nose
Long philtrum, large ears,
beaked nose
Skin Loose redundant
skin folds
Loose redundant skin
folds
Coarse face
Cardiovascular ARD, valvular
anomalies
SVAS, PPAS
Emphysema + +++
Genitourinary diverticula + +++
Gastro-intestinal
diverticula/tortuosity
- +
Inheritance AD AR
ARD, aortic root dilatation; SVAS, supravalvular aortic root stenosis; PPAS, peripheral
autosomal dominant; AR, autosomal recessive. References: [3-8,18-22].endoplasmatic reticulum stress (due to protein
misfolding), increased coacervation and elastin globule
formation leading to lower amounts of insoluble, ma-
ture elastin. Enhanced TGFβ signaling is probably
secondary to altered elastic fiber anatomy [3].
Two reports indicated molecular heterogeneity in
ADCL. In a single ADCL patient, a tandem duplication
in the FBLN5 gene was shown to result in secretion of
mutant protein, suggesting a dominant negative effect
[11]. However, mutant protein integration in the extra-
cellular matrix has been shown in FBLN5 related ARCL
type 1 [31] and carriers of these mutations do not have a
cutis laxa phenotype. A second report showed a muta-
tion in exon 25 of the ELN gene which encodes a
conserved cross-linking domain important for insoluble
elastin formation [10]. This patient also presented
with severe neurological involvement, which was not
attributed to his cutis laxa syndrome. His father carried
the same alteration, but did not exhibit any phenotype.
Future confirmation of these two defects may shed fur-
ther insights on the molecular heterogeneity of ADCL.
Until then, ADCL can be considered as a phenotypically
and genetically homogeneous disorder in which analysisutis laxa syndromes
ARCL type 1c ARCL type 1b
(LTBP4) (FBLN4)
Long philtrum, large ears, beaked nose, sparse
hair on temporal sides
Loose redundant skin folds Hyperextensible skin
Skin redundancy
PPAS, CPAS ARD, multiple arterial
aneurysms
+++ +/-
++ ?
+++ ?
AR AR
pulmonary artery stenosis; CPAS, common pulmonary artery stenosis; AD,
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instance.
Conclusion
This cohort of patients further indicates that ADCL is a
systemic disorder with a risk for major complications in-
cluding aortic root dilatation and pulmonary emphy-
sema, warranting regular follow-up. The molecular data
favor a single mutational mechanism resulting in a stable
C-terminal extension of the elastin protein.
Abbreviations
ADCL: Autosomal dominant Cutis Laxa; ARCL: Autosomal recessive cutis laxa;
ARD: Aortic rooth dilatation; ELN: Elastin; SVAS: Supravalvular aortic stenosis;
WBS: Williams-Beuren syndrome; TGFβ: Transforming Growth Factor β.
Competing interests
The authors declare no competing interests.
Authors’ contributions
SHR and BLC reviewed patients, designed the study and drafted the
manuscript. EB, MK, ASP, VL and DB reviewed patients. MR and PJC
performed and supervised the molecular analyses. JDB, FM, OMV and ADP
contributed to clinical assessment, sample collection and drafting of the
manuscript. CB reviewed patients, and contributed in the design of the
study. All authors have read and approved the final manuscript.
Acknowledgements
This work was supported by a Methusalem grant to ADP (BOF 08/01M01108
from the Ghent University and Flemish Government) providing funding to
perform the molecular analysis. JDB is a senior clinical investigator and BC
and FM are postdoctoral research fellows of the Fund for Scientific Research
– Flanders. OV has a BOF research fellowship from the Ghent University. We
are indebted to the families involved in this study as well as to REEL (Réseau
élastique), a French collaboration network on inherited diseases of the elastic
fibers, that supports research by providing logistic support in patient
assembly, evaluation and sample gathering and that supports patients in
daily life. Besides SHR, BLC, ADP and CB, the network further consists of
Romain Debret (romain.debret@ibcp.fr), Pascal Sommer (p.sommer@ibcp.fr),
Safa Saker (saker@genethon.fr), Alice Phan (alice.phan@chu-lyon.fr), Ludovic
Martin (LuMartin@chu-angers.fr), Frédéric Caux (frederic.caux@avc.aphp.fr)
and Marie-Claude Boiteux (mcjlboiteux@aol.com).
Author details
1Service de Dermatologie – Centre de référence national des Maladies
Génétiques à Expression Cutanée (MAGEC), INSERM U781, Hôpital Necker -
Enfants Malades, Université Paris V-Descartes, 149, rue de Sèvres 75743 Paris
Cedex 15, Paris, France. 2Center for Medical Genetics, Ghent University
Hospital, De Pintelaan 185, B-9000, Ghent, Belgium. 3Service de
Dermatologie, MAGEC Hôpital Saint-Louis, Paris, France. 4University Medical
Center St. Radboud, Nijmegen, the Netherlands. 5Academic Medical Center,
Amsterdam, the Netherlands. 6Groupe Hospitalier Du Havre – Department of
Medical Genetics, Le Havre, France. 7Institute of Medical Genetics, University
of Zürich, Zürich, Switzerland.
Received: 27 November 2012 Accepted: 14 February 2013
Published: 25 February 2013
References
1. Ewart AK, Morris CA, Atkinson D, Jin W, Sternes K, Spallone P, Stock AD,
Leppert M, Keating MT: Hemizygosity at the elastin locus in a
developmental disorder, Williams syndrome. Nat Genet 1993, 5:11–16.
2. Curran ME, Atkinson DL, Ewart AK, Morris CA, Leppert MF, Keating MT: The
elastin gene is disrupted by a translocation associated with
supravalvular aortic stenosis. Cell 1993, 73:159–168.
3. Callewaert B, Renard M, Hucthagowder V, Albrecht B, Hausser I, Blair E, Dias
C, Albino A, Wachi H, Sato F, et al: New insights into the pathogenesis ofautosomal-dominant cutis laxa with report of five ELN mutations.
Hum Mutat 2011, 32:445–455.
4. Rodriguez-Revenga L, Iranzo P, Badenas C, Puig S, Carrio A, Mila M: A novel
elastin gene mutation resulting in an autosomal dominant form of cutis
laxa. Arch Dermatol 2004, 140:1135–1139.
5. Szabo Z, Crepeau MW, Mitchell AL, Stephan MJ, Puntel RA, Yin Loke K, Kirk
RC, Urban Z: Aortic aneurysmal disease and cutis laxa caused by defects
in the elastin gene. J Med Genet 2006, 43:255–258.
6. Tassabehji M, Metcalfe K, Hurst J, Ashcroft GS, Kielty C, Wilmot C, Donnai D,
Read AP, Jones CJ: An elastin gene mutation producing abnormal
tropoelastin and abnormal elastic fibres in a patient with autosomal
dominant cutis laxa. Hum Mol Genet 1998, 7:1021–1028.
7. Urban Z, Gao J, Pope FM, Davis EC: Autosomal dominant cutis laxa with
severe lung disease: synthesis and matrix deposition of mutant
tropoelastin. J Invest Dermatol 2005, 124:1193–1199.
8. Zhang MC, He L, Giro M, Yong SL, Tiller GE, Davidson JM: Cutis laxa arising
from frameshift mutations in exon 30 of the elastin gene (ELN).
J Biol Chem 1999, 274:981–986.
9. Pober BR, Johnson M, Urban Z: Mechanisms and treatment of
cardiovascular disease in Williams-Beuren syndrome. J Clin Invest 2008,
118:1606–1615.
10. Graul-Neumann LM, Hausser I, Essayie M, Rauch A, Kraus C: Highly variable
cutis laxa resulting from a dominant splicing mutation of the elastin
gene. Am J Med Genet A 2008, 146A:977–983.
11. Markova D, Zou Y, Ringpfeil F, Sasaki T, Kostka G, Timpl R, Uitto J, Chu ML:
Genetic heterogeneity of cutis laxa: a heterozygous tandem duplication
within the fibulin-5 (FBLN5) gene. Am J Hum Genet 2003, 72:998–1004.
12. Kelleher CM, Silverman EK, Broekelmann T, Litonjua AA, Hernandez M, Sylvia
JS, Stoler J, Reilly JJ, Chapman HA, Speizer FE, et al: A functional mutation
in the terminal exon of elastin in severe, early-onset chronic obstructive
pulmonary disease. Am J Respir Cell Mol Biol 2005, 33:355–362.
13. Hu Q, Reymond JL, Pinel N, Zabot MT, Urban Z: Inflammatory destruction
of elastic fibers in acquired cutis laxa is associated with missense alleles
in the elastin and fibulin-5 genes. J Invest Dermatol 2006, 126:283–290.
14. Megarbane H, Florence J, Oliver Sass J, Schwonbeck S, Foglio M, de Cid R,
Cure S, Saker S, Megarbane A, Fischer J: An autosomal-recessive form of
cutis laxa is due to homozygous elastin mutations, and the phenotype
may be modified by a heterozygous fibulin 5 polymorphism. J Invest
Dermatol 2009, 129:1650–1655.
15. Loeys BL, Dietz HC, Braverman AC, Callewaert BL, De Backer J, Devereux RB,
Hilhorst-Hofstee Y, Jondeau G, Faivre L, Milewicz DM, et al: The revised
Ghent nosology for the Marfan syndrome. J Med Genet 2010, 47:476–485.
16. Kornak U, Reynders E, Dimopoulou A, van Reeuwijk J, Fischer B, Rajab A,
Budde B, Nurnberg P, Foulquier F, Lefeber D, et al: Impaired glycosylation
and cutis laxa caused by mutations in the vesicular H+-ATPase subunit
ATP6V0A2. Nat Genet 2008, 40:32–34.
17. Reversade B, Escande-Beillard N, Dimopoulou A, Fischer B, Chng SC, Li Y,
Shboul M, Tham PY, Kayserili H, Al-Gazali L, et al: Mutations in PYCR1 cause
cutis laxa with progeroid features. Nat Genet 2009, 41:1016–1021.
18. Callewaert B, Su CT, Van Damme T, Vlummens P, Malfait F, Vanakker O,
Schulz B, Mac Neal M, Davis EC, Lee JG, et al: Comprehensive clinical and
molecular analysis of 12 families with type 1 recessive cutis laxa.
Hum Mutat 2013, 34:111–121.
19. Renard M, Holm T, Veith R, Callewaert BL, Ades LC, Baspinar O, Pickart A,
Dasouki M, Hoyer J, Rauch A, et al: Altered TGFbeta signaling and
cardiovascular manifestations in patients with autosomal recessive cutis
laxa type I caused by fibulin-4 deficiency. Eur J Hum Genet 2010,
18:895–901.
20. Hucthagowder V, Sausgruber N, Kim KH, Angle B, Marmorstein LY, Urban Z:
Fibulin-4: a novel gene for an autosomal recessive cutis laxa syndrome.
Am J Hum Genet 2006, 78:1075–1080.
21. Loeys B, Van Maldergem L, Mortier G, Coucke P, Gerniers S, Naeyaert JM, De
Paepe A: Homozygosity for a missense mutation in fibulin-5 (FBLN5)
results in a severe form of cutis laxa. Hum Mol Genet 2002, 11:2113–2118.
22. Urban Z, Hucthagowder V, Schurmann N, Todorovic V, Zilberberg L, Choi J,
Sens C, Brown CW, Clark RD, Holland KE, et al: Mutations in LTBP4 cause a
syndrome of impaired pulmonary, gastrointestinal, genitourinary,
musculoskeletal, and dermal development. Am J Hum Genet 2009,
85:593–605.
23. Arlt G, Brooks DA, Isbrandt D, Hopwood JJ, Bielicki J, Bradford TM, Bindloss-
Petherbridge CA, von Figura K, Peters C: Juvenile form of
Hadj-Rabia et al. Orphanet Journal of Rare Diseases 2013, 8:36 Page 8 of 8
http://www.ojrd.com/content/8/1/36mucopolysaccharidosis VI (Maroteaux-Lamy syndrome). A C-terminal
extension causes instability but increases catalytic efficiency of
arylsulfatase B. J Biol Chem 1994, 269:9638–9643.
24. Choi BY, Kim DH, Chung T, Chang M, Kim EH, Kim AR, Seok J, Chang SO,
Bok J, Kim D, et al: Destabilization and Mislocalization of POU3F4 by C-
Terminal Frameshift Truncation and Extension Mutation. Hum Mutat
2013, 34:309–316.
25. Dickey DM, Yoder AR, Potter LR: A familial mutation renders atrial
natriuretic Peptide resistant to proteolytic degradation. J Biol Chem 2009,
284:19196–19202.
26. Komaru K, Ishida Y, Amaya Y, Goseki-Sone M, Orimo H, Oda K: Novel
aggregate formation of a frame-shift mutant protein of tissue-
nonspecific alkaline phosphatase is ascribed to three cysteine residues
in the C-terminal extension. Retarded secretion and proteasomal
degradation. FEBS J 2005, 272:1704–1717.
27. Soldovieri MV, Castaldo P, Iodice L, Miceli F, Barrese V, Bellini G, Miraglia del
Giudice E, Pascotto A, Bonatti S, Annunziato L, Taglialatela M: Decreased
subunit stability as a novel mechanism for potassium current
impairment by a KCNQ2 C terminus mutation causing benign familial
neonatal convulsions. J Biol Chem 2006, 281:418–428.
28. Bohm J, Heinritz W, Craig A, Vujic M, Ekman-Joelsson BM, Kohlhase J, Froster
U: Functional analysis of the novel TBX5 c.1333delC mutation resulting
in an extended TBX5 protein. BMC Med Genet 2008, 9:88.
29. Colige A, Sieron AL, Li SW, Schwarze U, Petty E, Wertelecki W, Wilcox W,
Krakow D, Cohn DH, Reardon W, et al: Human Ehlers-Danlos syndrome
type VII C and bovine dermatosparaxis are caused by mutations in the
procollagen I N-proteinase gene. Am J Hum Genet 1999, 65:308–317.
30. Smith LT, Wertelecki W, Milstone LM, Petty EM, Seashore MR, Braverman IM,
Jenkins TG, Byers PH: Human dermatosparaxis: a form of Ehlers-Danlos
syndrome that results from failure to remove the amino-terminal
propeptide of type I procollagen. Am J Hum Genet 1992, 51:235–244.
31. Hu Q, Loeys BL, Coucke PJ, De Paepe A, Mecham RP, Choi J, Davis EC,
Urban Z: Fibulin-5 mutations: mechanisms of impaired elastic fiber
formation in recessive cutis laxa. Hum Mol Genet 2006, 15:3379–3386.
doi:10.1186/1750-1172-8-36
Cite this article as: Hadj-Rabia et al.: Twenty patients including 7
probands with autosomal dominant cutis laxa confirm clinical and
molecular homogeneity. Orphanet Journal of Rare Diseases 2013 8:36.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
